FDA peptide advisers expected to support RFK Jr.’s legalization push

The Food and Drug Administration (FDA) has announced that it will be convening an outside panel of advisers to discuss the possibility of allowing compounding pharmacies to manufacture certain peptides. The meetings are scheduled to take place on July 23 and 24, with another meeting planned before the end of February 2027.

This decision comes after the FDA removed 19 peptides from a list of drugs that compounding pharmacies were previously allowed to produce back in 2023. The upcoming panel will specifically focus on whether to add back seven of these peptides. Additionally, a future meeting, which has yet to be scheduled, will address the potential reinstatement of five more peptides.

The effectiveness and safety of these peptides have been a topic of concern, as there is limited data available on their benefits. Despite this, these products have gained popularity, with endorsements from online influencers and even health secretary Robert F. Kennedy Jr. Kennedy recently expressed his desire to make these peptides more accessible during an interview with podcaster Joe Rogan in February.

As discussions around the manufacturing of peptides continue, it will be crucial for the FDA to carefully consider the potential risks and benefits associated with these products. Stay tuned for updates on the outcomes of the upcoming panel meetings and the future decisions regarding the production of peptides by compounding pharmacies.